Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) conference being held November 9-12, 2021 virtually and in Boston, and the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting held November 12-14, 2021 virtually and in Washington, D.C.
Among the data being presented at CTAD are twelve-month biomarker and clinical data from the open-label Phase 2 INFRONT-2 study evaluating AL001 in individuals with frontotemporal dementia due to progranulin gene mutation (FTD-GRN). Alector will also present data from its Phase 1 study of AL003 in healthy volunteers and participants with Alzheimer’s disease. AL003 is being developed in collaboration with its partner, AbbVie.
At SITC, Alector will provide an update on AL009, a first-in-class multi-Siglec inhibitor that enhances innate and adaptive immunity to cancer by blocking a critical glycan checkpoint pathway.
Alector plans to host a conference call to review these data and the progress across its pipeline on November 12, 2021, at 4:00 p.m. ET.
